FDA tells Novo Nordisk its Wegovy pill launch ad is false or misleading

The Wegovy pill, the first oral GLP-1 weight loss drug sold in the United States, got its television debut in a commercial that ran during the Golden Globes broadcast on 11 January 2026, as part of a Novo Nordisk campaign called "Live lighter" ^[1]. On 5 February 2026, the US Food and Drug Administration sent the company an Untitled Letter that described the ad as "false or misleading" ^[2].

Much of the agency's objection came down to the commercial's narration. Two lines — "Now you can live lighter by losing weight" and "It's a way forward" — "misleadingly imply additional weight loss compared with other currently approved GLP-1 treatments, when this has not been demonstrated," the FDA wrote ^[1].

The same phrases, the letter said, suggest gains that reach past physical weight loss, including "emotional relief, reduced psychological burden, hope, or direction for patients" ^[1]. Elsewhere in the letter, the agency said the ad presents oral Wegovy as having "superior efficacy and/or safety" relative to approved GLP-1 injections, which the evidence does not establish ^[2].

"These claims and presentations misleadingly imply that Wegovy in pill form uniquely enables patients to achieve outcomes that were not previously possible with other GLP-1 treatments for weight loss," the FDA wrote ^[2].

Two more issues were raised: the ad, in the agency's view, frames the drug as a "solution to broader life challenges" rather than a weight loss treatment, and it fails to deliver the major statement in audio and text at the same time ^[2].

The spot opens with the line "Meet Wegovy pill, the first and only FDA-approved GLP-1 weight loss pill," then shows people rollerblading, biking and riding amusement attractions, with a narrator saying, "Weight loss has never looked like this" ^[2]. Wegovy's active ingredient is semaglutide ^[1].

Novo Nordisk confirmed receiving the letter. Liz Skrbkova, the company's head of US media and stakeholder relations, noted that the commercial had been airing since launch and was not the ad the company ran during the Super Bowl ^[2]. "Novo Nordisk is committed to responsible advertising that is accurate, balanced and meets all FDA regulatory and compliance standards," she said, adding that the company believes in Wegovy and hopes patients who might benefit will talk with a healthcare professional ^[2].

The company's first Super Bowl commercial for the pill, which featured Kenan Thompson, DJ Khaled and Danielle Brooks trading jokes about whether they would take a pill to handle tasks like parallel parking or getting a cat out of a tree, drew no comment from the agency ^[2]. Whether the FDA will object to that ad has not been reported; it has not issued letters or remarks about Super Bowl commercials ^[2].

Why it matters for patients

Anyone weighing a daily pill against a weekly injection is now a target for advertising on both sides. The dispute here is not whether oral Wegovy works — the FDA has not questioned the drug's approval — but whether this commercial implied it works better than other GLP-1 medicines, or eases emotional burdens in ways they do not, claims the agency says have not been demonstrated ^[1][2].

No penalty, required corrective ad or other enforcement step beyond the letter has been disclosed ^[2]. Novo Nordisk says it is answering the agency's concerns ^[2]. The episode also illustrates a practical reality of a year with more GLP-1 advertising on television: patients may hear claims that regulators later challenge.

What happens next

Novo Nordisk says it is in the process of responding to the FDA ^[2]. What follows the 5 February letter, and whether the Super Bowl commercial draws similar attention, has not been reported ^[2].